Addressing blinding in classic psychedelic studies with innovative active placebos.
- Published in:
- International Journal of Neuropsychopharmacology, 2025, v. 28, n. 4, p. 1, doi. 10.1093/ijnp/pyaf023
- By:
- Publication type:
- Article
Works matching IS 14611457 AND DT 2025 AND VI 28 AND IP 4
Results: 5
1
2
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review.
- Published in:
- International Journal of Neuropsychopharmacology, 2025, v. 28, n. 4, p. 1, doi. 10.1093/ijnp/pyaf021
- By:
- Publication type:
- Article
3
Examination of the relationship between D-amino acid profiles and cognitive function in individuals with mild cognitive impairment: a machine learning approach.
- Published in:
- International Journal of Neuropsychopharmacology, 2025, v. 28, n. 4, p. 1, doi. 10.1093/ijnp/pyaf016
- By:
- Publication type:
- Article
4
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M<sub>1</sub>/M<sub>4</sub> muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
- Published in:
- International Journal of Neuropsychopharmacology, 2025, v. 28, n. 4, p. 1, doi. 10.1093/ijnp/pyaf015
- By:
- Publication type:
- Article
5
Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study.
- Published in:
- International Journal of Neuropsychopharmacology, 2025, v. 28, n. 4, p. 1, doi. 10.1093/ijnp/pyaf011
- By:
- Publication type:
- Article